Results 91 to 100 of about 5,799,531 (403)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway

open access: yesTechnology in Cancer Research and Treatment, 2019
Background: Tumor environment has been recognized to affect cancer cell progression, such as tumor-associated macrophages. However, increasing evidences suggest that tumor cells are capable of regulating polarization of tumor-associated macrophages.
Guanghui Lian   +5 more
semanticscholar   +1 more source

The current multidisciplinary management of rectal cancer

open access: yesAnnals of Gastroenterological Surgery
Multidisciplinary management of rectal cancer has rapidly evolved over the last several years. This review describes recent data surrounding total neoadjuvant therapy, organ preservation, and management of lateral pelvic lymph nodes. It then presents our
Neal Bhutiani   +9 more
doaj   +1 more source

Lack of Effect of Murine Norovirus Infection on a Mouse Model of Bacteria-Induced Colon Cancer [PDF]

open access: yes, 2011
Murine norovirus (MNV) is endemic in mouse research facilities in the United States and Europe, with a prevalence as high as 58% to 64%. Because of MNV's orofecal route of infection, clinically silent persistent infections in some mouse strains, and ...
Brabb, Thea   +5 more
core   +1 more source

Influence of dietary phytochemicals and microbiota on colon cancer risk. [PDF]

open access: yes, 2012
Colon cancer is the third most commonly diagnosed type of cancer in the United States. Lifestyle and dietary patterns influence colon cancer risk both positively and negatively.
MacDonald, Ruth   +2 more
core   +3 more sources

Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer [PDF]

open access: gold, 2021
Wagdy M. Eldehna   +10 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Pre-diagnostic plasma bile acid levels and colon cancer risk: A prospective study.

open access: yesJournal of the National Cancer Institute, 2019
BACKGROUND Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans.
T. Kühn   +43 more
semanticscholar   +1 more source

Histopathology report on colon cancer specimens; measuring surgical quality, an increasing stress for surgeons [PDF]

open access: yes, 2018
Introduction. Improving the quality of surgical resections by evaluating surgical specimens is probably the most important feedback a surgeon can receive.
Bilavschi, Karina   +5 more
core   +3 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy